There are many clinical trials evaluating the role of p38 as a biomarker and target for different diseases, with a considerable percentage dedicated to cancer treatment, where p38 is considered a promising target, either using p38-specific inhibitors alone or in combination with other chemotherapeutic agents [125] (Table 1). The gene discussed is MAPK1; the disease is cancer.